About Us

The powerful Unyvero technology was originated in Germany, and Unyvero products are manufactured by Curetis GmbH. In the USA, Unyvero products are exclusively distributed by OpGen, Inc.

Curetis GmbH is located near Stuttgart in the heartland of German high-tech industry, and it is now an OpGen Group company. Curetis GmbH has been developing and commercializing molecular diagnostic products for more than 10 years, designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.

In 2018, Curetis received FDA clearance for America’s first Lower Respiratory multiplex PCR diagnostic panel -the Unyvero LRT Panel for tracheal aspirate samples, followed by FDA clearance of the Unyvero LRT BAL for bronchoalveolar lavage samples in 2019. With theUnyvero LRT and LRT BAL, hospitals can diagnose serious Pneumonia infections and target effective antibiotic treatment with the help of syndromic testing faster. Faster, targeted treatment leads to reduced mortality, reduced healthcare costs and better utility of available antibiotics.

In 2020, Curetis combined its business with OpGen to build stronger diagnostic solutions for severe infections. In the USA,Unyvero products are exclusively distributed by OpGen, Inc.

Our OpGen Group company Ares Genetics GmbH offers next-generation solutions for infectious disease diagnostics and therapeutics thatare based on the combination of Next Generation Sequencing (NGS) with artificial intelligence powered data analytics. At Ares Genetics we have the vision to provide a universal solution that in any patient sample can identify any pathogen and accurately predict its susceptibility to anti-infective drug therapy. The ARES Technology Platform combines what we believe is the world’s most comprehensive databases on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence solutions. It will be further enhanced in depth and scope through its integration with the AcuitasLighthouse Platform.


We strive to deliver innovative diagnostic solutions to help clinicians swiftly combat severe infectious diseases.

By leveraging our powerful technologies, we envision a world that is no longer threatened by antibiotic resistant superbugs.